University of Chicago
Radiation Oncology residency · Chicago, IL · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is University of Chicago's research in radiation oncology, which the program shares with other departments and affiliated hospitals.
About University of Chicagoinstitution-wide radiation oncology research
Radiation Oncology publications from University of Chicago and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
300
works per year
17th of 47 radiation oncology residency programs
+19.6%
2-year growth
13th of 47 radiation oncology residency programs
27.0%
in top 10% of field (works before 2025)
5th of 47 radiation oncology residency programs
46.1%
cited above world average
15th of 47 radiation oncology residency programs
Works per year · * 2026 so far
Oncology · 1,084Radiology, Nuclear Medicine and Imaging · 408
Radiation Oncology research topics at University of Chicago
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 270
- CAR-T cell therapy research 209
- Cardiac Imaging and Diagnostics 67
- Pancreatic and Hepatic Oncology Research 60
- Global Cancer Incidence and Screening 49
- Colorectal Cancer Screening and Detection 44
- Advanced MRI Techniques and Applications 41
- Radiomics and Machine Learning in Medical Imaging 40
Most cited at University of Chicago since 2024
All radiation oncology papers there on OpenAlex
- The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023Lisa M Force et al. · The Lancet · 2025 · PubMed · cited 498
- Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosisXiaobing Wang et al. · Cell · 2024 · PubMed · cited 327
- Radiotherapy, immunity, and immune checkpoint inhibitorsConnor M. Lynch et al. · The Lancet Oncology · 2024 · PubMed · cited 217
- CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis et al. · Nature · 2024 · PubMed · cited 201
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine TumorsJennifer Ai-wen Chan et al. · New England Journal of Medicine · 2024 · PubMed · cited 177
- Global, regional, and national burden of breast cancer among females, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023Kayleigh Pavitra Bhangdia et al. · The Lancet Oncology · 2026 · PubMed · cited 174
- Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trialArmin Ghobadi et al. · The Lancet · 2025 · PubMed · cited 160
- Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath et al. · Journal of Clinical Oncology · 2025 · PubMed · cited 152
- Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant TherapyHannah M. Thompson et al. · JAMA Network Open · 2024 · PubMed · cited 149
- Radiotherapy and immunologyLiangliang Wang et al. · The Journal of Experimental Medicine · 2024 · PubMed · cited 133